It allows continued monitoring of the benefit/risk balance of the medicinal product. Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

When suggestions are available use up and down arrows to review and ENTER to select. Specifically, the risk for methemoglobinemia may be increased. There are no data reported indicating the possibility of adverse effects during the human pregnancy, however, the tablets should not be administered during pregnancy or lactation unless considered to be essential. Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Combinations of these agents may increase the likelihood of significant methemoglobinemia.

Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Tolerance and cross-tolerance to other nitrates may occur. Pyridoxine therapy should be initiated with onset of such symptoms.• Cardiovascular disease: Use with caution in patients with coronary artery disease (CAD); tachycardia and hypotension (due to hydralazine) may potentiate myocardial ischemia and angina, especially in patients with hypertrophic cardiomyopathy.• Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (ACCF/AHA [Gersh, 2011]).• Pulmonary hypertension: Use with caution in pulmonary hypertension; may cause hypotension.• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.

Any CYP3A4 substrate used with stiripentol requires closer monitoring.Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.The following events were reported in the A-HeFT Study using the combination isosorbide dinitrate/hydralazine product. Some combinations may be specifically contraindicated. Consult drug interactions database for more detailed information.• Tolerance: When nitrates are used in combination with hydralazine for HF, tolerance to nitrate therapy is less of a concern (Gogia 1995).Blood pressure (standing and sitting/supine), heart rate; CBC and antinuclear antibody (ANA) titers (if symptoms of systemic lupus erythematosus occur)Hydralazine crosses the placenta (ESC [Regitz-Zagrosek 2018]).See individual monographs for additional information.• Lupus like rash on the cheeks or other body parts, sunburn easy, muscle or joint pain, chest pain or shortness of breath, or swelling in the arms or legs.• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. • Peripheral oedema in patients treated for left ventricular failure. The major metabolites are isosorbide 2-mononitrate and isosorbide 5-mononitrate which both possess vasodilatory activity and may contribute to the activity of the parent compound. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. We comply with the HONcode standard for trustworthy health information - • Dosage may be reduced in the elderly especially where there is impairment of renal or hepatic function. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents.